Lefitolimod

N/A

Report date: 2026/04/08 20:02:35
NME

Base Information

Drug NameLefitolimod
Drug Alias Name来托莫德lefitolimodumlefitolimod来菲托莫德MGN-1703
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionImmunomodulatorsToll like receptor 9 agonists
TargetsToll like receptor 9
Therapy Area/IndicationsSmall Cell Lung CarcinomaColorectal NeoplasmsMelanoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[14] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMologen AgGilead Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences IncAarhus University
Inactive CompaniesMologen AgThe University Of Texas MD Anderson Cancer Center
Active IndicationsHIV Infections
Inactive IndicationsSmall Cell Lung CarcinomaColorectal NeoplasmsMelanoma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A